GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Material
Publisher
Person/Organisation
Language
Years
FID
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
    Elsevier BV ; 2023
    In:  Kidney International Reports ( 2023-8)
    Details
    In: Kidney International Reports, Elsevier BV, ( 2023-8)
    Type of Medium: Online Resource
    ISSN: 2468-0249
    URL: Article
    DOI: 10.1016/j.ekir.2023.08.034
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2023
    detail.hit.zdb_id: 2887223-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Open-Switch Fault Diagnosis Method in Voltage-Source Inverters Based on Phase Currents
    Institute of Electrical and Electronics Engineers (IEEE) ; 2019
    In:  IEEE Access Vol. 7 ( 2019), p. 63619-63625
    Details
    In: IEEE Access, Institute of Electrical and Electronics Engineers (IEEE), Vol. 7 ( 2019), p. 63619-63625
    Type of Medium: Online Resource
    ISSN: 2169-3536
    URL: Journal
    URL: Article
    DOI: 10.1109/Access.6287639
    DOI: 10.1109/ACCESS.2019.2913164
    Language: Unknown
    Publisher: Institute of Electrical and Electronics Engineers (IEEE)
    Publication Date: 2019
    detail.hit.zdb_id: 2687964-5
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 3
    Online Resource
    Online Resource
    慢性B型肝炎患者服用Tenofovir Alafenamide治療之療效和安全性—系統性回顧和統合分析
    Angle Publishing Co., Ltd. ; 2023
    In:  輔仁醫學期刊 Vol. 21, No. 2 ( 2023-06), p. 013-025
    Details
    In: 輔仁醫學期刊, Angle Publishing Co., Ltd., Vol. 21, No. 2 ( 2023-06), p. 013-025
    Abstract: 〈p〉背景與目的：慢性B型肝炎（chronic hepatitis B, CHB）患者若未接受治療，很可能會併發嚴重的併發症。目前治療CHB患者療效最佳的藥物為Tenofovir disoproxil fumarate（TDF），但長期服用會有較高骨密度流失及腎毒性反應。Tenofovir alafenamide（TAF）為Tenofovir的新型藥物，過去用以治療HIV患者的臨床試驗中，顯示與TDF相比，效果相似但安全性較佳。TAF已經開始用於治療一般族群的慢性B型肝炎，安全性需要有更robust的實證資料。本研究旨在探討在治療CHB患者時，TAF是否較TDF，有較好的療效以及更佳的安全性。研究方法：利用PubMed、Cochrane和Embase進行TDF和TAF比較的隨機對照試驗文獻搜尋，搜尋日至2022年3月前出版之英文文獻。統合分析以random-effects model估算療效和安全性，統計軟體選用Review Manager Version 5.4。研究結果：本研究共收錄4篇文獻，在療效部分，TAF相較於TDF在HBV DNA〈29 IU/ml (RR=1.00, 95%CI= 0.96-1.03)和HBeAg消失(RR=1.19, 95%CI= 0.95-1.50)未達統計上顯著差異；HBeAg血清學轉換則有統計顯著差異(RR=1.39，95%CI= 1.04-1.83)。在髖骨密度與脊骨密度變化，和血清肌酸酐濃度變化之安全性指標，TAF變化程度皆較TDF小，TAF較TDF有較佳的安全性。結論：本研究結果顯示在治療CHB患者上TAF與TDF相比，在療效結果具非劣性，安全性結果則為TAF優於TDF。因此TAF有機會可以作為臨床上的另一種選擇，未來也建議應使用真實世界的資料進行長期慢性副作用的驗證。〈/p〉 〈p〉 〈/p〉〈p〉Background and purpose: Nowadays, the most effective drug for the treatment of chronic hepatitis B (CHB) patients is Tenofovir disoproxil fumarate (TDF), how-ever long-term use will lead to high bone density loss and nephrotoxicity. Tenofovir alafenamide (TAF) is a noval drug of Tenofovir. In the past clinical trials for the treatment of HIV patients, it has shown similar effects but better safety than TDF. TAF has been used to treat CHB in the general population, but more robust evidence is needed for safety. This study aims to investigate whether TAF has better efficacy and better safety than TDF in the treatment of CHB patients. Methods: PubMed, Cochrane and Embase were used to conduct a literature search of randomized con-trolled trials comparing TDF and TAF, and the English language literature published by March 2022 was searched. Meta-analysis used random-effects model to estimate efficacy and safety, and the statistical software was Review Manager Version 5.4. Results: A total of four articles were included in this study. In the efficacy, TAF com-pared with TDF in HBV DNA〈29 IU/ml (RR=1.00, 95%CI=0.96-1.03) and HBeAg loss (RR=1.19, 95 %CI=0.95-1.50) was not statistically significant; HBeAg serocon-version was statistically significant (RR=1.39, 95%CI=1.04-1.83). In the safety indi-cators of changes in hip BMD and spine BMD, and changes in serum creatinine con-centration, the degree of change in TAF was smaller than TDF, and TAF had better safety than TDF. Conclusion: The results of this study show that TAF is non-inferior to TDF in the treatment of CHB patients in terms of efficacy outcomes and TAF is superior to TDF in safety outcomes. Therefore, TAF has the opportunity to be used as another clinical option.〈/p〉 〈p〉 〈/p〉
    Type of Medium: Online Resource
    ISSN: 1810-2093 , 1810-2093
    Uniform Title: The efficacy and safety of Tenofovir Alafenamide on patients with chronic hepatitis B virus infection: a systematic review and meta-analysis
    URL: Article
    DOI: 10.53106/181020932023062102002
    Language: Unknown
    Publisher: Angle Publishing Co., Ltd.
    Publication Date: 2023
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 4
    Online Resource
    Online Resource
    Association of Parenteral Anticoagulation Therapy With Outcomes in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Without Invasive Therapy: Findings from the Improving Care for Cardiovascular Disease in China (CCC) project
    Wiley ; 2021
    In:  Clinical Pharmacology & Therapeutics Vol. 110, No. 4 ( 2021-10), p. 1119-1126
    Details
    In: Clinical Pharmacology & Therapeutics, Wiley, Vol. 110, No. 4 ( 2021-10), p. 1119-1126
    Abstract: Our previous study showed that parenteral anticoagulation therapy (PACT) in the context of aggressive antiplatelet therapy failed to improve clinical outcomes in patients undergoing percutaneous coronary intervention for non–ST‐segment elevation acute coronary syndrome (NSTE‐ACS). However, the role of PACT in patients managed medically remains unknown. This observational cohort study enrolled patients with NSTE‐ACS receiving medical therapy from November 2014 to June 2017 in the Improving Care for Cardiovascular Disease in China‐Acute Coronary Syndrome project. Eligible patients were included in the PACT group and non‐PACT group. The primary outcomes were in‐hospital all‐cause mortality and major bleeding. The secondary outcome included minor bleeding. Among 23,726 patients, 8,845 eligible patients who received medical therapy were enrolled. After adjusting the potential confounders, PACT was not associated with a lower risk of in‐hospital all‐cause mortality (adjusted odds ratio (OR), 1.25; 95% confidence interval (CI), 0.92–1.71; P  = 0.151). Additionally, PACT did not increase the incidence of major bleeding or minor bleeding (major bleeding: adjusted OR, 1.04; 95% CI, 0.80–1.35; P  = 0.763; minor bleeding: adjusted OR, 1.27; 95% CI, 0.91–1.75; P  = 0.156). The propensity score analysis confirmed the primary analyses. In patients with NSTE‐ACS receiving antiplatelet therapy, PACT was not associated with a lower risk of in‐hospital all‐cause mortality or a higher bleeding risk in patients with NSTE‐ACS receiving non‐invasive therapies and concurrent antiplatelet strategies. Randomized clinical trials are warranted to reevaluate the safety and efficacy of PACT in all patients with NSTE‐ACS who receive noninvasive therapies and current antithrombotic strategies.
    Type of Medium: Online Resource
    ISSN: 0009-9236 , 1532-6535
    URL: Issue
    URL: Article
    DOI: 10.1002/cpt.v110.4
    DOI: 10.1002/cpt.2370
    RVK:
    XA 36900
    Language: English
    Publisher: Wiley
    Publication Date: 2021
    detail.hit.zdb_id: 2040184-X
    SSG: 15,3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 5
    Online Resource
    Online Resource
    Making a Little History with the Chang Gung Cleft Lip Repair
    Ovid Technologies (Wolters Kluwer Health) ; 2015
    In:  Plastic and Reconstructive Surgery - Global Open Vol. 3, No. 6 ( 2015-06), p. e420-
    Details
    In: Plastic and Reconstructive Surgery - Global Open, Ovid Technologies (Wolters Kluwer Health), Vol. 3, No. 6 ( 2015-06), p. e420-
    Type of Medium: Online Resource
    ISSN: 2169-7574
    URL: Article
    DOI: 10.1097/GOX.0000000000000403
    Language: English
    Publisher: Ovid Technologies (Wolters Kluwer Health)
    Publication Date: 2015
    detail.hit.zdb_id: 2723993-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 6
    Online Resource
    Online Resource
    Association of Dipeptidyl Peptidase-4 Inhibitors Use with Reduced Risk of Hepatocellular Carcinoma in Type 2 Diabetes Patients with Chronic HBV Infection
    MDPI AG ; 2023
    In:  Cancers Vol. 15, No. 4 ( 2023-02-10), p. 1148-
    Details
    In: Cancers, MDPI AG, Vol. 15, No. 4 ( 2023-02-10), p. 1148-
    Abstract: Previous studies have indicated that HBV infection and T2DM are the factors that increase the risk of developing HCC. The experimental evidence has shown that antiglycemic agents may reduce the risk of HCC. However, the effect of dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) on the risk of HCC in T2DM patients with chronic HBV infection remains unclear. In this retrospective cohort study, we extracted patients with T2DM and chronic HBV infection from the National Health Insurance Research Database (NHIRD) in Taiwan. The cases were divided into DPP-4 inhibitors use and non-use groups, according to whether they received DPP-4 inhibitors treatment, and the risk of HCC was compared between the two groups. At the end of the follow-up, approximately 2.33% of DPP-4 inhibitors users had received an HCC diagnosis compared with 3.33% of non-DPP-4 inhibitors users (p 〈 0.0001). After multivariate adjustment, DPP-4 inhibitors users showed a significant reduction in HCC risk (adjusted hazard ratios (aHRs): 0.53; 95% confidence intervals (CIs): 0.44–0.65). In conclusion, this population-based retrospective cohort study indicated that, in T2DM patients with chronic HBV infection, the use of DPP-4 inhibitors significantly reduced the risk of developing HCC compared with non-DPP-4 inhibitors use.
    Type of Medium: Online Resource
    ISSN: 2072-6694
    URL: Article
    DOI: 10.3390/cancers15041148
    Language: English
    Publisher: MDPI AG
    Publication Date: 2023
    detail.hit.zdb_id: 2527080-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 7
    Online Resource
    Online Resource
    Favorable Lip and Oral Cancer Mortality-to-Incidence Ratios in Countries with High Human Development Index and Expenditures on Health
    MDPI AG ; 2021
    In:  International Journal of Environmental Research and Public Health Vol. 18, No. 11 ( 2021-06-03), p. 6012-
    Details
    In: International Journal of Environmental Research and Public Health, MDPI AG, Vol. 18, No. 11 ( 2021-06-03), p. 6012-
    Abstract: Background: The incidence rates of lip and oral cancer have continued to increase, and prognosis is associated with a country’s socioeconomic status. The mortality-to-incidence ratio (MIR) is a reasonable indicator of disparities in cancer screening and treatment. In this study, we aimed to understand the association between economic status and cancer prognosis. Methods: Data were obtained from the Global Cancer Observatory (GLOBOCAN) and the World Health Organization (WHO). The MIRs were compared to evaluate the correlation with the human development index (HDI), the current health expenditure (CHE), and the ratio of CHE over gross domestic product (CHE/GDP) disparities via Spearman’s rank correlation coefficient. Results: The results showed that Asia had the most cases and deaths. In addition, they showed a significant association (p 〈 0.001, p = 0.005, and p 〈 0.001, respectively) of the crude rate (CR) of incidence with the HDI, the CHE, and the CHE/GDP. However, their associations with mortality rate (p = 0.303, p = 0.997, and p = 0.101) were not significant. Regarding the correlation of the MIRs, the results revealed a significant association with the HDI, the CHE, and the CHE/GDP (p 〈 0.001, p 〈 0.001, and p 〈 0.001, respectively). Conclusion: Countries with higher HDI, CHE per capita, and CHE/GDP tend to have lower MIRs, which indicates favorable clinical outcomes.
    Type of Medium: Online Resource
    ISSN: 1660-4601
    URL: Article
    DOI: 10.3390/ijerph18116012
    Language: English
    Publisher: MDPI AG
    Publication Date: 2021
    detail.hit.zdb_id: 2175195-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 8
    Online Resource
    Online Resource
    Secular Trends in Incidence of Esophageal Cancer in Taiwan from 1985 to 2019: An Age-Period-Cohort Analysis
    MDPI AG ; 2022
    In:  Cancers Vol. 14, No. 23 ( 2022-11-27), p. 5844-
    Details
    In: Cancers, MDPI AG, Vol. 14, No. 23 ( 2022-11-27), p. 5844-
    Abstract: In Taiwan, the age-standardized incidence of EC, especially esophageal squamous cell carcinoma (ESCC), has increased substantially during the past thirty years. We described the incidence trends of EC from 1985–2019 by an average annual percentage change (AAPC) and age-period-cohort model by using Taiwan Cancer Registry data. Age-period-cohort modeling was used to estimate the period and cohort effects of ESCC and esophageal adenocarcinoma (EAC). The Spearman’s correlation coefficient was used to analyze the correlation between age-adjusted incidence rates of EC and the prevalence of risk factors from national surveys. The results showed the incidence rate of ESCC in men (AAPC = 4.2, 95% CI = 3.1–5.4, p 〈 0.001) increased prominently from 1985–1989 to 2015–2019 while that of EAC in men (AAPC = 1.2, 95% CI = 0.9–1.5, p 〈 0.001) and ESCC in women (AAPC = 1.7, 95% CI = 1.4–2.1, p 〈 0.001) increased to a lesser degree. Increased period effects were observed in ESCC in men, ESCC in women, and EAC in men. High correlations were found between the risk factors and the increased birth-cohort effects of ESCC (p 〈 0.05). To conclude, the incidence of ESCC in both sex and EAC in men increased with statistical significance in recent decades. The increased prevalence of risk factors from approximately 1970–1995 could explain the increased cohort effects of ESCC.
    Type of Medium: Online Resource
    ISSN: 2072-6694
    URL: Article
    DOI: 10.3390/cancers14235844
    Language: English
    Publisher: MDPI AG
    Publication Date: 2022
    detail.hit.zdb_id: 2527080-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 9
    Online Resource
    Online Resource
    Age Specific Risks of Uterine Cancer in Type 2 Diabetes and Associated Comorbidities in Taiwan
    MDPI AG ; 2022
    In:  Cancers Vol. 14, No. 19 ( 2022-10-07), p. 4912-
    Details
    In: Cancers, MDPI AG, Vol. 14, No. 19 ( 2022-10-07), p. 4912-
    Abstract: Introduction: The global incidence of uterine cancer has increased substantially in recent decades. We evaluated if the trend of increasing prevalence of diabetes mellitus (DM) and obesity are attributed to the development of uterine cancer. Methods: Using data derived from the National Health Insurance database and Taiwan Cancer Registry, multivariate Cox proportional hazards regression models were adapted to analyze the risk factors of uterine cancer with potential confounding variables. Results: There were a total of 5,104,242 women aged 30–70 years enrolled in the study and 147,772 of them were diagnosed with DM during 2005–2007. In a total of 11 years of follow-up, 14,398 subjects were diagnosed with uterine cancer. An elevated risk of uterine cancer was observed in women with DM of all ages (HR 1.66, 95% CI 1.53–1.81, p 〈 0.0001). The effect of DM was highest at age 30–39 years (RR 3.05, 95% CI 2.35–3.96, p 〈 0.0001). In the group of 〈 50 years old, DM patients had at least a twofold higher risk of developing uterine cancer (HR 2.39, 95% CI 2.09–2.74, p 〈 0.0001). Subjects among all ages diagnosed with polycystic ovary syndrome (PCOS) (HR 2.91, 95% CI 2.47–3.42, p 〈 0.0001), obesity (HR 2.13, 95% CI 1.88–2.41, p 〈 0.0001), and those undergoing hormone replacement therapy (HRT) (HR 1.60, 95% CI 1.33–1.93, p 〈 0.0001) were also positively associated with uterine cancer. Positive associations of hyperlipidemia (HR 1.33, 95% CI 1.22–1.46, p 〈 0.0001) and statin use (HR 1.27, 95% CI 1.12–1.44, p = 0.0002) on uterine cancer were only observed in subjects 〈 50 years. On the contrary, hyperlipidemia was negatively associated with uterine cancer in subjects ≥50 years (HR 0.91, 95% CI: 0.84–0.98, p = 0.0122). Conclusions: DM is in general the most important risk factor for uterine cancer, especially in premenopausal women. Obesity, PCOS, HPL, statin use, and HRT were also associated with uterine cancer in subjects younger than 50 years. Premenopausal women with DM and respective comorbidities should be aware of the development of uterine cancer.
    Type of Medium: Online Resource
    ISSN: 2072-6694
    URL: Article
    DOI: 10.3390/cancers14194912
    Language: English
    Publisher: MDPI AG
    Publication Date: 2022
    detail.hit.zdb_id: 2527080-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 10
    Online Resource
    Online Resource
    Clinical Use of Acid Suppressants and Risk of Dementia in the Elderly: A Pharmaco-Epidemiological Cohort Study
    MDPI AG ; 2020
    In:  International Journal of Environmental Research and Public Health Vol. 17, No. 21 ( 2020-11-09), p. 8271-
    Details
    In: International Journal of Environmental Research and Public Health, MDPI AG, Vol. 17, No. 21 ( 2020-11-09), p. 8271-
    Abstract: Background: Results of studies regarding the potential link between acid suppressant use and dementia risk are inconsistent. This study aimed to evaluate the association of cumulative exposure to histamine 2 receptor antagonists (H2RAs) and proton pump inhibitors (PPIs) with dementia risk in an Asian older cohort aged ≥65 years. Methods: Patients initiating H2RA (the H2RA user cohort, n = 21,449) or PPI (the PPI user cohort, n = 6584) and those without prescription for H2RA (the H2RA non-user cohort, n = 21,449) or PPI (the PPI non-user cohort, n = 6584) between 1 January 2000 and 31 December 2005 without a prior history of dementia were identified from Taiwan’s National Health Insurance Research Database (NHIRD). The outcome of interest was all-cause dementia. Patients’ exposure to H2RAs or PPIs was followed-up from dates of initial prescription to the earliest outcome of incident dementia, death, or the end of 2013. Potential associations between acid suppressant use and dementia risk were analyzed using time-dependent Cox regression estimated hazard ratios (HRs) and 95% confidence intervals (CIs). Results: After mutual adjustment for H2RA and PPI use and other potential confounders, patients with H2RA use had significantly higher risk of developing dementia as compared to those not treated with H2RAs (adjusted HR, 1.84; 95% CI, 1.49–2.20). Likewise, PPI users had significantly elevated risk of dementia compared to PPI non-users (adjusted HR, 1.42; 95% CI, 1.07–1.84). Conclusions: Our results indicate that exposures to H2RAs and PPIs are associated with increased dementia risk.
    Type of Medium: Online Resource
    ISSN: 1660-4601
    URL: Article
    DOI: 10.3390/ijerph17218271
    Language: English
    Publisher: MDPI AG
    Publication Date: 2020
    detail.hit.zdb_id: 2175195-X
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...